Cases & Deals

ArunA Bio raises $13.3 million in Common Stock offering

Clients ArunA Bio, Inc.

Jones Day represented ArunA Bio, Inc., a manufacturer of technologies in human stem cell research for use in drug discovery and development, in connection with its offering and sale of up to $13.3 million of Common Stock. Proceeds from the financing will be used to support the continued development of ArunA Bio’s neural exosome delivery platform and pipeline of novel neural exosome therapies for the treatment of neurodegenerative diseases such as ALS and Huntington’s Disease, as well as stroke.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.